These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38534065)

  • 1. Rh immune globulin immunoprophylaxis after RhD-positive red cell exposure in RhD-negative patients via transfusion: A survey of practices.
    Lu W; Stephens L; Shmookler A; O'Brien K; Karp JK; Hermelin D; Bakhtary S; Almozain N; George M; Fung M
    Transfusion; 2024 May; 64(5):839-845. PubMed ID: 38534065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitigation strategies for anti-D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: a survey of NCCN
    Poston JN; Sugalski J; Gernsheimer TB; Marc Stewart F; Pagano MB
    Vox Sang; 2020 May; 115(4):334-338. PubMed ID: 32080868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rh(O)D immune globulin products for prevention of alloimmunization during pregnancy.
    Aitken SL; Tichy EM
    Am J Health Syst Pharm; 2015 Feb; 72(4):267-76. PubMed ID: 25631833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive anti-C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series.
    Sostin N; Ross R; Balbuena-Merle R; Hendrickson JE; Tormey CA
    J Clin Apher; 2020 Jun; 35(3):224-226. PubMed ID: 32110829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates?
    Atoyebi W; Mundy N; Croxton T; Littlewood TJ; Murphy MF
    Br J Haematol; 2000 Dec; 111(3):980-3. PubMed ID: 11122163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inaccurate doses of R immune globulin after rh-incompatible fetomaternal hemorrhage: survey of laboratory practice.
    Ramsey G;
    Arch Pathol Lab Med; 2009 Mar; 133(3):465-9. PubMed ID: 19260751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Rh sensitization in the context of trauma: two case reports.
    Werch JB
    J Clin Apher; 2010; 25(2):70-3. PubMed ID: 20027640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obstetric and Newborn Weak D-Phenotype RBC Testing and Rh Immune Globulin Management Recommendations: Lessons From a Blinded Specimen-Testing Survey of 81 Transfusion Services.
    Ramsey G; Park YA; Eder AF; Bobr A; Karafin MS; Karp JK; King KE; Pagano MB; Schwartz J; Szczepiorkowski ZM; Souers RJ; Thomas L; Delaney M
    Arch Pathol Lab Med; 2023 Jan; 147(1):71-78. PubMed ID: 35486492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of multiple passively acquired alloantibodies following infusions of IV Rh immune globulin.
    Rushin J; Rumsey DH; Ewing CA; Sandler SG
    Transfusion; 2000 May; 40(5):551-4. PubMed ID: 10827257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Platelet transfusion and immunization anti-Rh1: implication for immunoprophylaxis].
    Chambost H
    Transfus Clin Biol; 2014 Nov; 21(4-5):210-5. PubMed ID: 25282489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rh Immunoprophylaxis for Women With a Serologic Weak D Phenotype.
    Virk M; Sandler SG
    Lab Med; 2015; 46(3):190-4. PubMed ID: 26199257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists.
    Sandler SG; Roseff SD; Domen RE; Shaz B; Gottschall JL
    Arch Pathol Lab Med; 2014 May; 138(5):620-5. PubMed ID: 24786120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose of 100 IU intravenous anti-D gammaglobulin is effective for the prevention of RhD immunisation after RhD-incompatible single donor platelet transfusion.
    Zeiler T; Wittmann G; Zingsem J; Weisbach V; Zimmermann R; Eckstein R
    Vox Sang; 1994; 66(3):243. PubMed ID: 8036796
    [No Abstract]   [Full Text] [Related]  

  • 14. RhD-positive red blood cell allocation practice to RhD-negative patients before and during the COVID-19 pandemic.
    Tanhehco YC; Fung M; Hermelin D; Becker J; Lu W
    Am J Clin Pathol; 2024 Sep; ():. PubMed ID: 39287493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of D sensitization after mismatched transfusion of blood components: toward optimal use of RhIG.
    Ayache S; Herman JH
    Transfusion; 2008 Sep; 48(9):1990-9. PubMed ID: 18564395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guideline No. 448: Prevention of Rh D Alloimmunization.
    Fung-Kee-Fung K; Wong K; Walsh J; Hamel C; Clarke G
    J Obstet Gynaecol Can; 2024 Apr; 46(4):102449. PubMed ID: 38553007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-D Alloimmunization Following Rhesus-Incompatible Platelet Transfusion in a Myelodysplastic Syndrome Patient.
    Hanafi R; Zulkeflee RH; Hassan MN; Saidin NIS; Adzahar S; Hassan R
    Cureus; 2024 Mar; 16(3):e57165. PubMed ID: 38681415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets.
    Molnar R; Johnson R; Sweat LT; Geiger TL
    Transfusion; 2002 Feb; 42(2):177-82. PubMed ID: 11896332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer type predicts alloimmunization following RhD-incompatible RBC transfusions.
    Arora K; Kelley J; Sui D; Ning J; Martinez F; Lichtiger B; Tholpady A
    Transfusion; 2017 Apr; 57(4):952-958. PubMed ID: 28191636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of RhD-alloimmunization after the transfusion of multiple RhD-positive primary red blood cell-containing products.
    Yazer MH; Triulzi DJ; Sperry JL; Seheult JN
    Transfusion; 2021 Jul; 61 Suppl 1():S150-S158. PubMed ID: 34269438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.